Under the „135“ program, WuXi and Huawei will comply with the relevant provisions of the State Food and Drug Administration (CFDA), through cooperation with third-party security life sciences cloud platform vendors, joint development for Chinese Medicine Program and precise data exchange standards and frameworks.
China Bio news release, May 25, 2016